Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MLK4
is a member of the mixed-lineage family of kinases that regulate the JNK, p38, and ERK kinase signaling pathways.
MLK4
mutations have been identified in various human cancers, including frequently in colorectal cancer, where their function and pathobiological importance have been uncertain. In this study, we assessed the functional consequences of
MLK4
mutations in colon tumorigenesis. Biochemical data indicated that a majority of
MLK4
mutations are loss-of-function (LOF) mutations that can exert dominant-negative effects. In seeking to understand the abrogated activity of these mutants, we elucidated a new
MLK4
catalytic domain structure. To determine whether
MLK4
is required to maintain tumorigenic phenotypes, we reconstituted its signaling axis in
colon cancer
cells harboring
MLK4
-inactivating mutations. We found that restoring
MLK4
activity reduced cell viability, proliferation, and colony formation in vitro and delayed tumor growth in vivo. Mechanistic investigations established that restoring the function of
MLK4
selectively induced the JNK pathway and its downstream targets, cJUN, ATF3, and the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B. Our work indicates that
MLK4
is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in
colon cancer
.
...
PMID:Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. 2663 68